New drug combo tested in battle against aggressive blood cancer
NCT ID NCT05471700
Summary
This study tested the safety and effectiveness of combining two drugs, azacitidine and venetoclax, for adults aged 45-65 newly diagnosed with a fast-growing blood cancer called acute myeloid leukemia (AML). All 40 participants received the drug combination to try to put the cancer into remission. Researchers tracked how well patients responded, how long the response lasted, and survival for up to three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanfang Hospital of Southern Medical University
Guanzhou, Guandong, 510250, China
Conditions
Explore the condition pages connected to this study.